急性髓系白血病患者中 XS15 佐剂的多肽疫苗接种 (AML-VAC-XS15)
已通过一线治疗获得完全缓解的急性髓系白血病 (AML) 患者接受 TLR1/2 配体 XS15 辅助的多肽疫苗接种
The aim of this Phase I study is to evaluate the immunogenicity along with safety and toxicity as well as first efficacy of a multi-peptide vaccine adjuvanted with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG (AML-VAC-XS15) in AML patients who have achieved CR or CRi with first line treatment.
研究概览
详细说明
Peptide vaccine: Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides.
The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen (headed by Juliane Walz).
Treatment schedule:
The vaccine cocktail will be administered subcutaneously (s.c.) together with the (toll-like receptor )TLR1/2 ligand XS15 (50 µg) emulsified in Montanide ISA 51 VG (1:1) as adjuvant.
Two vaccinations within a 6-week interval are planned, with the option of one additional booster in case of insufficient response after the first two vaccinations.
Peptide vaccination will take place in AML patients that have achieved a morphological complete remission (CR) or a complete remission with incomplete blood count recovery (CRi) with standard first line treatment. Minimal residual disease (MRD) positivity is permitted.
Vaccination will start 4-28 weeks after last application of intensive chemotherapy). Any maintenance treatment, e.g. with oral azacytidine or midostaurin, or ongoing low intensity therapy, e.g. with HMA, venetoclax etc. is permitted, can be applied throughout the vaccination and continued after study treatment according to the treating physician's decision.
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Juliane Walz, Prof. Dr.
- 电话号码:83275 +49 7071 29
- 邮箱:kketi@med.uni-tuebingen.de
研究联系人备份
- 姓名:Helmut Salih, Prof.Dr.
- 电话号码:83275 +49 7071 29
- 邮箱:kketi@med.uni-tuebingen.de
学习地点
-
-
Baden-Wurttemberg
-
Tübingen、Baden-Wurttemberg、德国、72076
- 招聘中
- University Hospital Tuebingen
-
接触:
- Juliane Walz, Prof. Dr.
- 电话号码:+49 07071 29 87305
- 邮箱:kketi@med.uni-tuebingen.de
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Males or females aged ≥18 years of age
-
Existence of a written informed consent
-
Documented diagnosis of AML according to WHO guidelines
- morphological complete remission (CR) or complete remission with incomplete blood count recovery (CRi)
- positive MRD is permitted
- completion of previous intensive therapy (first vaccination 4-28 weeks after last application of chemotherapy) or
- ongoing low intensity treatment with e.g. hypomethylating agents (HMA), venetoclax, etc.
- ongoing maintenance treatment with e.g. oral azacytidine or midostaurin is permitted.
- not eligible for allogeneic stem cell transplantation
-
Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2
-
Adequate organ function laboratory values.
- bilirubin ≤ 3 times upper limit range (exception isolated indirect hyperbilirubinemia (Morbus Gilbert-Meulengracht)).
- alanine aminotransferase (ALT) and aminotransferase (AST), ≤ 5 times upper limit range
- creatinine clearance GFR > 30 ml/min (CKD-EPI)
- platelets > 50.000/μl
- absolute CD3+ T cell count ≥ 200/μl
-
negative serological hepatitis B test or negative PCR in case of positive serological test without evidence of an active infection, negative testing of hepatitis C RNA, negative HIV test within 6 weeks prior to study inclusion
-
Female patients of child bearing potential (FCBP) and male patients with partners of child bearing potential, who are sexually active, must agree to the use of two effective forms (at least one highly effective method) of contraception (for more detailed information see chapter 5.7 Contraception, pregnancy, sperm donation and nursing). This should be started from the signing of the informed consent and be continued until 3 months (both female and male patients) after last vaccination).
-
For FCBP two negative pregnancy tests (sensitivity of at least 25 mlU/mL) prior to first application of first vaccination, one at screening and the other prior (< 24 h) to first vaccination
-
Postmenopausal or evidence of non-child-bearing status
Exclusion Criteria:
-
Pregnant or breastfeeding.
-
Unwilling or unable to follow the study schedule for any reason.
-
Chemotherapy or other systemic therapy or radiotherapy, up to 14 days prior to the first dose of study drug (ongoing maintenance treatment or low intensity treatment is permitted).
-
Concurrent or previous treatment within 28 days in another interventional clinical trial with an investigational anticancer therapy or any other investigational therapy, which would interfere with the study's primary and secondary endpoints.
-
Major surgery within 28 days of dosing of study drug.
-
Treatment with immunotherapy agents within 28 days of dosing of study drug.
-
Diagnosis of acute promyelocytic leukemia (APL)
-
Autoimmune disease that requires or has required treatment with systemic immunosuppressive treatments, except low dose corticosteroids (< 10 mg/ day), in the past 1 year.
-
Prior history of malignancies, other than AML/myelodysplastic syndrome (MDS), unless the subject has been free of the disease for
≥ 2 years. Exceptions include the following: basal cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, histological finding of prostate cancer of TNM stage T1
-
Prior stem cell allograft or organ transplantation
-
Ongoing or active infection (including SARS-CoV-2)
-
Have received any live vaccination within 28 days prior to the first dose of AML-VAC-XS15.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Multipeptide Vaccination
The vaccine cocktail will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 (50 μg) emulsified in Montanide ISA 51 VG (1:1) as adjuvant. Two vaccinations within a 6-week interval are planned, with the option of one additional booster in case of insufficient response after the first two vaccinations. Peptide vaccination will take place in AML patients that have achieved a morphological complete remission (CR) or a complete remission with incomplete blood count recovery (CRi) with standard first line treatment. MRD positivity is permitted. Vaccination will start 4-28 weeks after last application of intensive chemotherapy). Any maintenance treatment, e.g. with oral azacytidine or midostaurin, or ongoing low intensity therapy, e.g. with HMA, venetoclax etc. is permitted, can be applied throughout the vaccination and continued after study treatment according to the treating physician's decision. |
Multi-peptide vaccine cocktail comprising 9 different immunopeptidome-defined mutated and non-mutated AML/ leukemia stem and progenitor cell (LSC)-associated HLA class I and HLA class II peptides. The vaccine cocktail is synthesized and formulated in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen.
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
immunogenicity
大体时间:Visit 1( Day 0); Visit 2 (Day 42); End of Treatment (Day 70); Follow-Up (Day160); Follow-Up 1(Day 188); Follow-Up 2 (Day 250)
|
Blood will be taken before peptide vaccination and during vaccination phase and follow-ups at each visit IFN-gamma ELISPOT Counts Percentage of patients with induction of an AML-VAC-XS15-specific specific T-cell response until End of study visit (EOS) compared to baseline as determined by IFNγ ELISPOT. |
Visit 1( Day 0); Visit 2 (Day 42); End of Treatment (Day 70); Follow-Up (Day160); Follow-Up 1(Day 188); Follow-Up 2 (Day 250)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.